Cells (Mar 2024)

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells

  • Matteo Giulietti,
  • Francesco Piva,
  • Monia Cecati,
  • Serena Maggio,
  • Michele Guescini,
  • Tiziana Saladino,
  • Laura Scortichini,
  • Sonia Crocetti,
  • Miriam Caramanti,
  • Nicola Battelli,
  • Emanuela Romagnoli

DOI
https://doi.org/10.3390/cells13060479
Journal volume & issue
Vol. 13, no. 6
p. 479

Abstract

Read online

Extracellular vesicles (EVs) are small lipid particles secreted by almost all human cells into the extracellular space. They perform the essential function of cell-to-cell communication, and their role in promoting breast cancer progression has been well demonstrated. It is known that EVs released by triple-negative and highly aggressive MDA-MB-231 breast cancer cells treated with paclitaxel, a microtubule-targeting agent (MTA), promoted chemoresistance in EV-recipient cells. Here, we studied the RNA content of EVs produced by the same MDA-MB-231 breast cancer cells treated with another MTA, eribulin mesylate. In particular, we analyzed the expression of different RNA species, including mRNAs, lncRNAs, miRNAs, snoRNAs, piRNAs and tRNA fragments by RNA-seq. Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.

Keywords